Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis
| العنوان: | Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis |
|---|---|
| المؤلفون: | Lukas Ronner, Angela G. Fleischman, Ruben A. Mesa, Matthew Chiaramonte, John Mascarenhas, Jason Gotlib, Revathi Kollipara, Mark L. Heaney, Mahta Salehi, Jenny Nguyen, Megan Randall, Cecelia Perkins, Douglas Tremblay, Robyn M. Scherber, Olivia Siwoski, Casey O'Connell, Nikolai A. Podoltsev, Annie Kwok Hung, Lindsey Behlman, Kimia Ziadkhanpour, Andrew T. Kuykendall, Shelby Meckstroth, Ami Dave, Erin Moshier, Jamile M. Shammo, Ronald Hoffman, Michelle Janania Martinez, Mitchell Harrison, Sagar Patel, Paola Fernandez Soto, Michael P. Grant, Hellen Nguyen, Abdulraheem Yacoub |
| المصدر: | Blood. 135:1696-1703 |
| بيانات النشر: | American Society of Hematology, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Leukocytosis, Immunology, Hematocrit, Biochemistry, Young Adult, Polycythemia vera, Internal medicine, Humans, Medicine, Young adult, Myelofibrosis, Polycythemia Vera, Survival rate, Aged, Retrospective Studies, Aged, 80 and over, medicine.diagnostic_test, business.industry, Thrombosis, Retrospective cohort study, Cell Biology, Hematology, Middle Aged, Prognosis, medicine.disease, Survival Rate, Leukemia, Myeloid, Acute, Primary Myelofibrosis, Myelodysplastic Syndromes, Female, medicine.symptom, business, Follow-Up Studies |
| الوصف: | There are unresolved questions regarding the association between persistent leukocytosis and risk of thrombosis and disease evolution in polycythemia vera (PV), as much of the published literature on the topic does not appropriately use repeated-measures data or time-dependent modeling to answer these questions. To address this knowledge gap, we analyzed a retrospective database of 520 PV patients seen at 10 academic institutions across the United States. Taking hematologic laboratory data at ∼3-month intervals (or as available) for all patients for duration of follow-up, we used group-based trajectory modeling to identify latent clusters of patients who follow distinct trajectories with regard to their leukocyte, hematocrit, and platelet counts over time. We then tested the association between trajectory membership and hazard of 2 major outcomes: thrombosis and disease evolution to myelofibrosis, myelodysplastic syndrome, or acute myeloid leukemia. Controlling for relevant covariates, we found that persistently elevated leukocyte trajectories were not associated with the hazard of a thrombotic event (P = .4163), but were significantly associated with increased hazard of disease evolution in an ascending stepwise manner (overall P = .0002). In addition, we found that neither hematocrit nor platelet count was significantly associated with the hazard of thrombosis or disease evolution. |
| تدمد: | 1528-0020 0006-4971 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c52862302a480a9fb967c12f777312e https://doi.org/10.1182/blood.2019003347 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....7c52862302a480a9fb967c12f777312e |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15280020 00064971 |
|---|